Takeda and Regeneron continue to tap into Adimab’s capabilities

By Maggie Lynch

- Last updated on GMT

(Image: Getty/MangoStar_Studio)
(Image: Getty/MangoStar_Studio)

Related tags Takeda Regeneron Biopharmaceutical discovery services Bispecific antibodies Partnership

Adimab expands partnerships with Takeda and Regeneron to enable biopharmaceutical companies with discovery and optimization capabilities.

Adimab will transfer its platform​ to Takeda Pharmaceuticals for the discovery and optimization of antibody and non-antibody-based protein therapeutics.

The two companies have been collaborating since 2016 and this agreement to transfer the platform serves as an expansion to the original agreement.

According to a statement made by Tillman Gerngross, CEO of Admiab, the company has initiated approximately 25 programs per year internally that involve discovery, optimization, and bispecifics, all of which use its CD3 antibodies.

Through the transfer, Takeda will have license at multiple research sites for discovery and optimization of modalities across various therapeutic areas.

The Adimab Platform enables user access to the internal capability to engineer different complex molecules in its pipeline diversification strategy in biologics and modalities for use without any target restrictions. Additionally, the agreement will grant Takeda access to human antibody libraries.

Robert Mabry, head of global biologics research at Takeda said in a statement that Adimab’s antibody discovery platform will help Takeda diversify its pipeline beyond small molecules and expand its modalities for monoclonal antibody (mAb) therapeutics along with other mechanisms of action enabled by antibody binders.

Takeda will also receive continued improvements to the Adimab Platform, including access to new antibody libraries.

Related news

Related products

show more

Designing an Optimal APAC Clinical Supply Chain

Designing an Optimal APAC Clinical Supply Chain

Catalent | 08-Mar-2023 | Infographic

With clinical study activity increasing across the Asia-Pacific region, it is important for sponsors—both in APAC and globally—to understand the broader...

How Sponsors Reduce Chaos in Decentralized Trials

How Sponsors Reduce Chaos in Decentralized Trials

Florence Healthcare | 08-Mar-2023 | Insight Guide

89% of research sponsors currently use and expect to continue the use of decentralized technologies and methods, according to our state of the industry...

Plan for success with process liquid and buffer preparation

Plan for success with process liquid and buffer preparation

Thermo Fisher Scientific - Process Liquid Preparation Services | 21-Feb-2023 | Technical / White Paper

Setting the groundwork for successful scale-up is essential for getting a therapeutic to market quickly and efficiently, but navigating the unknowns associated...

Enhance your cGMP chemical supply chain

Enhance your cGMP chemical supply chain

Thermo Fisher Scientific – Production Chemicals and Services | 09-Feb-2023 | Technical / White Paper

Supply chain issues have real, quantifiable impacts on biomanufacturers. However, the right support can make a cGMP supply chain operate seamlessly. Thermo...

Related suppliers

Follow us


View more